Document Type
Article
Department
Cardiology; Office of the Provost
Abstract
Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.
Publication (Name of Journal)
Pharmaceutics
DOI
10.3390/pharmaceutics15020459
Recommended Citation
Hermel, M.,
Lieberman, M.,
Slipczuk, L.,
Rana, J. S.,
Virani, S. S.
(2023). Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-The future is here. Pharmaceutics, 15(2), 459.
Available at:
https://ecommons.aku.edu/provost_office/538
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Comments
Pagination is not provided by the author/publisher.